Multiple confirmed partial and minor responses observed in patients with SGCContinuing very good safety profile, with removal of the lifetime ...
LONDON and PHILADELPHIA, April 14, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a ...
Avacta said on Monday that updated clinical data for its AVA6000 cancer therapy showed encouraging early efficacy signals in ...
Good morning, and welcome to the Avacta Group Plc Investor Presentation. [Operator Instructions] Due to the high attendance on today's call, the company may not be in a position to answer every ...
Avacta Group plc ( (GB:AVCT)) has provided an announcement. Avacta Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, is developing its proprietary pre|CISION® peptide drug ...
Good afternoon, ladies and gentlemen, and welcome to the Avacta Group plc Interim Results Investor Presentation. [Operator Instructions] Due to the significant attendance on today's call, the company ...
(Alliance News) - Avacta Group PLC on Monday announced the opening of a phase 1 trial for AVA6103, a peptide-drug conjugate. The London-based life sciences company said the conjugate will be evaluated ...
Avacta Therapeutics has reported progress across its cancer drug pipeline and strengthened its finances as it pushes towards key clinical data milestones later this year. AIM-list ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results